

Screen filtration pressures (±S.E.M.).

days. The results were the same whether s.f.p. was measured on samples maintained at storage temperature or on samples allowed to warm to ambient temperature first.

Measurements of catecholamines, serotonin, and A.D.P. concentrations and pH suggest that the pattern of platelet release and/or degradation was similar at all three temperatures, but that it was more striking at 1°C. One explanation for the lack of aggregation at room temperature may be that, in the absence of the cold stimulus, platelet release is slower so that by the time the plasma concentrations of released A.D.P., catecholamines, and serotonin are high enough to induce platelet aggregation, the platelets are unaggregable, perhaps due to a much reduced pH or loss of viability.

With efficient microfiltration, platelet aggregation may be of little consequence for many routine transfusions of whole blood. However if cold storage is to continue, the striking difference in aggregation seen between 1° and 4°C suggests that the storage temperature should be no lower than 4°C.

The work is part of a project funded by the Medical Research Council. The blood packs were kindly donated by McGraw Laboratories.

W. E. Dunn Unit of Cardiology, Keele University, Keele, Staffordshire ST5 5BG and North Staffordshire Royal Infirmary

R. A. OAKES G. WRIGHT J. M. SANDERSON

## HB<sub>5</sub>Ag IN RENAL DISEASE

SIR,—Renal disease has often been associated with hepatitis-B-antigen positive liver diseases. Brzosko et al., however, identified HB, Ag-antibody complexes in 50% of sera and 56% of renal-biopsy samples of 32 children with immune-complex glomerulonephritis (G.N.) and/or nephrotic syndrome but without clinical liver disease.

In the past four years we have examined 276 patients with G.N., nephrotic syndrome, and other kidney diseases for the presence of HB<sub>s</sub>Ag in serum and kidney. All patients were adults, 171 being males and 105 females. 7 had histories compatible with acute icteric hepatitis, 6 had received transfusions, and 6 had been treated with steroids and immunosuppressives. Only 5 patients had increased transaminases during the period of observation. We tested sera for HB<sub>s</sub>Ag by passive hæmagglutination ('Hepanosticon') and for anti-HB<sub>s</sub>Ag-antibody by immunoelectroosmophoresis. Kidney-biopsy tissue was studied by indirect immunofluorescence first with rabbit anti-HB<sub>s</sub>Ag antiserum

TABLE I—HBAG IN SERA AND KIDNEY BIOPSIES OF 276 ADULT RENAL PATIENTS

Diagnosis		HB <sub>s</sub> Ag positivity in		
	No.	Serum	Kidney.	Both
Primary G.N.:				
Diffuse				
Minimal proliferative				2000
intercapillary	37	0	0	0
Endocapillary/acute/				1992
proliferative	1	0	0	0
Mesangioproliferative	55	11	6	3
Mesangioproliferative	-			
with crescents	7	0 .	1	0
Membranous	17	3	4	3
Membranoproliferative	26	6	6	3 0
Berger disease	32	5	10	3
Focal	31	3 6 5 3 2	0	0
Focal sclerosing	9	. 2	1	0
G.N. associated with				
systemic disease:	_			
S.L.E.	7	0	2	0
Schönlein-Henoch	11	2	1 - 3	1 - 3 -
End-stage kidney	12	1	2	1
Other renal diseases				
Chronic pyelonephritis	10	1	0	0
Chronic interstitial				
nephritis	4	1	2	1
Secondary amyloidosis	3	0	0	0
Primary amyloidosis	2	0	0	0
Hereditary nephritis	4 3 2 9	1	2 0 0 0	0
Multiple myeloma	3	0	0	0
Total	276	36	37	15

The broken lines encompass immune-complex G.N.

(Behring, Marburg) and, then with fluorescein-labelled goat anti-rabbit-7S-globulin (Cappel, Downingtown). Specificity was checked by blocking experiments and by simultaneous staining of a known HB-Ag-positive liver section. Immunohistochemical analysis of kidney tissue was done by direct immunofluorescence using fluoresceinlabelled anti-human IgG, IgM, IgA, IgE, C3, and fibrinogen (Hyland, Costa Mesa).

Table I summarises the results. HB<sub>s</sub>Ag was identified in 13.0% of sera and in 13.4% of kidney tissue. These figures were slightly higher in 196 patients with immune-complex G.N. (primary G.N. without minimal change and G.N. associated with systemic diseases), being 16.3% for serum and 16.8% for kidney, and much lower (5%) and 5%) for the patients with "other renal diseases". In a parallel study HB antigenæmia was identified in 45 (0.45%) of sera from 10 000 healthy blood-donors. Except in 1 patient, no anti-HB<sub>s</sub>Ag antibody was noted in the sera. In 20 of the 32 immune-complex glomerulonephritic patients with HB<sub>s</sub> antigenæmia we re-examined sera after 6–10 months and found only 10 positive cases. In contrast to what Brzosko et al.¹ found in children, there was

TABLE II—COMPARISON OF DATA ON THE HB<sub>s</sub>Ag POSITIVITY IN GLOMERULONEPHRITIS

•	HB <sub>s</sub> Ag positivity (%) in		
Series	Serum	Kidney	
Brzosko et al.1*	50	56.2	
Vos et al. <sup>2</sup>	20-3	N.D.	
Reznikoff-Etievant and Lagrue3*	6.8	N.D.	
Conte and Fournic <sup>4</sup>	0	31	
Guardia et al.5	7.8	N.D.	
Powell et al.6	14.2	. N.D.	
Nagy et al.	16.3	16.3	

N.D.=not done

<sup>1.</sup> Brzosko, W. J., Krawczynski, K., Nazarewicz, T., Morzycka, M., Nowo-sawski, A. Lancet, 1974, ii, 477.

<sup>2.</sup> Vos, G. H., Grobbelaar, B. G., Milner, L. V. S. Afr. med. J. 1973, 47, 911.

Reznikoff-Etievant, M. F., Lagrue, G. Lancet, 1971, ii, 234.
 Conte, J. J., Fournie, G. J. Nouv. Presse méd. 1975, 4, 429.

<sup>5.</sup> Guardia, J., Pedreira, J. D., Martinez-Vázquez, J. M., Vidal, M. T., Vilardell, M., Caralos, A., Ferrer, E., Bacardi, R. ibid. 1975, 4, 2923.

<sup>6.</sup> Powell, K. C., Meadows, R., Anders, R., Draper, C. C., Lauer, C. Aust. N. Z. Jl Med. 1977, 7, 243.

<sup>\*</sup>Only cases of immune-complex glomerulonephritis were considered.

no predominance of HB<sub>s</sub>Ag positivity in our adult membranous and membranoproliferative patients (table 1).

Table II compares our data on HB<sub>s</sub>Ag positivity in G.N. with those obtained by other workers. Differences in age, geographic location, methods, and immune sera used may account for the different results.

Besides HB<sub>s</sub> antigenæmia we found renal HB<sub>s</sub>Ag positivity in some patients with immune-complex glomerulonephritis. Deposits of HB<sub>s</sub>Ag were seen in the same location as immuno-globulins and C3 suggesting that HB<sub>s</sub>Ag immune complexes may be implicated in the pathogenesis of G.N. in adults as well as children. The infection was anicteric in most of our cases. We recommend examination of the sera and kidney in all nephritic patients in order to detect HB<sub>s</sub>Ag components of immune-complex G.N.

2nd Department of Medicine, and Department of Pathology, University Medical School, Pécs 7621, Hungary; and Blood Transfusion Service, Pécs Judit Nagy
G. Bajtai
Hilda Brasch
T. Süle
Maria Ambrus
G. Deák
A. Hamori

## AGEING KIDNEY

SIR,—I read Professor McLachlan's paper (July 15, p. 143) with interest. My study in elderly women suggests that one factor which may accelerate renal ageing is bacteriuria. Two groups of elderly women were compared: one group had a very high frequency of significant bacteriuria (75%) and the other had a frequency of 24%. The kidneys of the group with a 75% incidence of significant bacteriuria were radiologically shorter, weighed less at necropy, and, on histological examination, had a greater percentage of completely obsolescent glomeruli.

Charing Cross Hospital (Fulham), London W6 8RF

J. R. CURTIS

## SCREENING FOR REFLUX

SIR,—You conclude (July 1, p. 23) that there is, as yet, no strong case for widespread radiological screening in young children. We agree, but would like to add some comments on the radiological investigation of children with urinary-tract infection (U.T.I.).

While few people now subscribe to the view that reflux by itself damages the kidney and that the incidence of reflux warrants general population screening, most would agree that other major urological abnormalities can severely damage the kidney. u.t.i. is often the first (only) early symptom of such an abnormality, which should be detected and corrected early in life if renal function is to be preserved.<sup>2</sup>

In a screening survey in the neonatal intensive-care unit of Lausanne University Hospital<sup>3</sup> we found bacteriuria in 43 out of 1762 neonates, 36 being males. Clinical symptoms suggestive of U.T.I. were present in 34, while only 9 were symptom-free. Radiological examination of the kidneys and urinary pathways demonstrated abnormalities in 15 out of 31 patients studied. Reflux was present in 11 and major malformations in 4.

Since asymptomatic U.T.I. is rare in the newborn, and since, on the other hand, major abnormalities of the urinary tract are a threat to the morphological and functional integrity of the kidney, we concluded that routine survey of bacteriuria in symptom-free neonates was not essential, that a thorough search for symptoms suggestive of U.T.I. in neonates would be

1. Curtis, J. R. M.D. thesis, University of London, 1968.

more helpful than routine screening for bacteriuria, and that all neonates presenting with proven U.T.I. should be investigated radiologically.

Division of Nephrology,
Pædiatric Service,
Centre Hospitalier Universitaire Vaudois,
1011 Lausanne, Switzerland
Children's Hospital,
C.H.C.-C.E.L.A.S.,
Coimbra, Portugal


J.-P. GUIGNARD
M. MAHERZI

A. TORRADO

## 1α-HYDROXY DERIVATIVES OF VITAMIN D, AND RENAL FUNCTION

SIR,—Dr Winterborn and his colleagues (July 15, p. 150) suggest that administration of 1α-hydroxyvitamin D<sub>3</sub> (1α-OHD<sub>3</sub>) adversely affects renal function in patients with chronic renal failure. Since this agent has now found a place in the treatment of renal bone disease, their conclusions, if correct, have important clinical implications, particularly if 1α-OHD<sub>3</sub> and 1,25-dihydroxycholecalciferol (1,25[OH]<sub>2</sub>D<sub>3</sub>) become widely used.

There are several problems in evaluating the effects of a drug on renal function in patients with progressive renal failure, including difficulties in judging the natural history of the kidney disease, the precision of measurements of renal function, and difficulties in separating direct effects of the drug



Serial measurements of plasma-creatinine in an adolescent with progressive renal failure due to membranoproliferative glomerulonephritis.

Plasma-creatinine is plotted against time on logarithmic (top) and exponential coordinates (bottom) before (0) and during treatment ( $\bullet$ ) with  $1\alpha$ -OHD<sub>3</sub>. The upper diagram shows that the rate of change of plasma-creatinine accelerated during treatment with  $1\alpha$ -OHD<sub>3</sub>. Assuming that deterioration of renal function would have continued exponentially had  $1\alpha$ -OHD<sub>3</sub> been withheld, then the onset of end-stage renal failure was apparently hastened by one year. The lower figure shows that if the rate of renal impairment is assumed to be hyperbolic, then any effect of  $1\alpha$ -OHD<sub>3</sub> on renal function is less evident. Because of the limited number of observations and the variation in plasma levels of creatinine, the natural history in this, and most patients, is difficult to predict.

Mayor, G., Genton, N., Torrado, A., Guignard, J.-P. Pediatrics, 1975, 56, 740.

<sup>3.</sup> Maherzi, M., Guignard, J.-P., Torrado, A. ibid. (in the press).